Background
Methods
Virus strains, reference DNA, and samples preparing and extracting
Real-time qPCR assay
RPA oligonucleotides and conditions
Name | Sequence (5′ –3′) | Genome location (KF661979.1) |
---|---|---|
CaPV Fe1 | CATTGTCTGATTTAATTTTCGTGTTGGTGTTTCCT | 377–411 |
CaPV Fe2 | CGTGTTGGTGTTTCCTTTTAATTTATACAATAGTA | 396–430 |
CaPV Fe3 | TGTTTCCTTTTAATTTATACAATAGTATAGCTAAA | 404–438 |
CaPV Re1 | ATCAATGTTATAAATGACATGCTATTGTAAAAACC | 493–527 |
CaPV Re2 | CAATAGCATGTCATTTATAACATTGATGAGTATTG | 501–535 |
CaPV Re3 | TATCTATCAATACTCATCAATGTTATAAATGACAT | 508–546 |
CaPV Pe | TAAACAATGGAGTTTGGGAGATTGTTTGTG(FAM- | 435–486 |
dT)A(THF)A(BHQ1-dT)TCAAAGCTATGTTTTAC-P | ||
CaPV Fn1 | CATTGTCTGATTTAATTTTCGTGTTGGTGTTTCCT | 377–411 |
CaPV Fn2 | CGTGTTGGTGTTTCCTTTTAATTTATACAATAGTA | 396–430 |
CaPV Fn3 | TGTTTCCTTTTAATTTATACAATAGTATAGCTAAA | 404–438 |
CaPV Rn1 | Biotin-ATCAATGTTATAAATGACATGCTATTGTAAAAACC | 493–527 |
CaPV Rn2 | Biotin-CAATAGCATGTCATTTATAACATTGATGAGTATTG | 501–535 |
CaPV Rn3 | Biotin-TATCTATCAATACTCATCAATGTTATAAATGACAT | 508–546 |
CaPV Pn | FAM-AACAATGGAGTTTGGGAGATTGTTTGTGTA-THF-ATTCAAAGCTATGTTTTAC-P | 435–486 |
Sensitivity and specificity of CaPV real-time RPA and CaPV RPA LFD assays
Virus family | Virus specie | Virus strain | Real-time RPA | RPA LFD | Real-time qPCR |
---|---|---|---|---|---|
Poxviridae | Capripox | GTPV AV40 | 4.6 min | pos | 19(CT) |
GTPV AV41 | 4.6 min | pos | 20(CT) | ||
GTPV GS-V1 | 5 min | pos | 20(CT) | ||
Capripox | SPPV Gulang2009 | 5.3 min | pos | 21(CT) | |
SPPV Jingtai2011 | 5 min | pos | 21(CT) | ||
SPPV Hubei | 5.3 min | pos | 22(CT) | ||
Poxviridae | ORFV | ORFV/Vaccine/CHA | neg | neg | neg |
ORFV | ORFV/HB/CHA | neg | neg | neg | |
Paramyxovirinae | PPRV | Nigeria 75/1 | neg | neg | neg |
Picornaviridae | FMDV | FMDV/O/CHA | neg | neg | neg |
FMDV | FMDV/A/CHA | neg | neg | neg |
Results
Sensitivity and specificity of CaPV real-time RPA assay
Sample name | Real-time qPCR (CT) | real-time RPA(min) | RPA LFD |
---|---|---|---|
liver 1 | 22 | 3.6 | + |
liver 2 | 27 | 4.3 | + |
liver 3 | 26 | 4 | + |
lung 1 | 31 | 7.6 | + |
lung 2 | 29 | 7.3 | + |
lung 3 | 24 | 4 | + |
stomach 1 | 26 | 4.3 | + |
stomach 2 | 28 | 4.3 | + |
stomach 3 | 32 | 8.3 | + |
kidney 1 | 22 | 4 | + |
kidney 2 | 25 | 4.6 | + |
kidney 3 | 29 | 7.3 | + |
lymphatic nodes 1 | 30 | 8 | + |
lymphatic nodes 2 | 21 | 3.3 | + |
lymphatic nodes 3 | 23 | 3.6 | + |
spleen 1 | 24 | 4.3 | + |
spleen 2 | 26 | 5 | + |
spleen 3 | 29 | 7.6 | + |
skin 1 | 22 | 4 | + |
skin 1 | 27 | 6.3 | + |
skin 1 | 28 | 6.6 | + |
nasal swab 1 | 25 | 6 | + |
nasal swab 2 | 26 | 6.3 | + |
nasal swab 3 | 28 | 7 | + |
Sensitivity and specificity of CaPV RPA LFD assay
Performance of CaPV real-time RPA and RPA LFD assay on clinical samples
clinical sample | Real-time RPA | RPA LFD | Real-time (qPCR) | |||
---|---|---|---|---|---|---|
Positive | Negative | Positive | Negative | Positive | Negative | |
Liver | 6 | 12 | 6 | 12 | 6 | 12 |
Lung | 5 | 9 | 5 | 9 | 5 | 9 |
Kidney | 12 | 13 | 12 | 13 | 12 | 13 |
Spleen | 5 | 5 | 5 | 5 | 6 | 4 |
Skin | 5 | 15 | 5 | 15 | 5 | 15 |
Blood | 3 | 17 | 3 | 17 | 3 | 17 |
Total | 36 | 71 | 36 | 71 | 37 | 70 |